Efficacy and safety of PM8002, a bispecific antibody targeting PD …
网页2024年5月29日 · Since 2021, a Phase Ib/IIa trial was conducted in China to assess the safety and efficacy of PM8002, a bispecific antibody that targets both PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors.
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody ...
网页2023年5月31日 · Background: PM8002 is a bispecific antibody targeting both PD-L1 and VEGF-A. We had completed dose escalation from 1mg/kg to 45mg/kg and had not found DLT/MTD. In a Phase Ib dose expansion and Phase IIa studies we are evaluating the safety and preliminary anti-tumor activity of PM8002 as a monotherapy.
网页assess the safety and efficacy of PM8002, a bispecific antibody that targets both PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors. Preliminary clinical data was presented at SITC2022 (abstract #725) and ASCO2023 (abstract #2536). Here, we present an update of our study for cervical cancer and PROC cohorts. Methods: Patients ...
725 Phase I safety and preliminary efficacy of PM8002 in subjects …
网页PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here we present the results from a Phase I first-in-human dose-escalation and ongoing expansion study of PM8002 in advanced solid tumors.
网页PM8002 combined with nab-paclitaxel showed encouraging antitumor activity regardless of PD-L1 status and good safety profile as a first-line therapy for TNBC patients.
网页PM8002 is a bispecific antibody target-ing PD-L1 and VEGF-A. Here we present the results from a Phase I first-in-human dose-escalation and ongoing expansion study of PM8002 in advanced solid tumors.
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody ...
网页2023年6月1日 · One example is PM8002, a bispecific antibody that combines PD-L1 inhibition with VEGF blockade. The early phase II results of PM8002 and paclitaxel combination treatment showed an impressive ...
1992P A phase II safety and efficacy study of PM8002 (anti-PD-L1 …
网页There is an unmet medical need for SCLC patients that progress on or after first-line platinum-based therapy. PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here, we present our results from a phase II study of PM8002 in combination with paclitaxel as second-line treatment for SCLC.
Biotheus Enters Into Strategic Partnership with BioNTech to …
网页2023年11月6日 · PM8002 has demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment...
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, …
网页PM8002 is a bispecific antibody targeting both PD-L1 and VEGF-A. Previous published data indicated that PM8002 has a tolerable safety profile and potential anti-tumor activity in a variety of solid tumors (SITC2022 abstract #725 and ASCO2023 abstract #2536).